
Shares of drug distributor Cencora COR.N rise 5.7% to $307.50
Co raises annual adj.profit forecast on strong demand for costly specialty medicines and weight-loss drugs
Expects 2025 adj.profit to be between $15.70 and $15.95 per share, up from its previous expectation of $15.30 to $15.60 per share
Q2 revenue at its U.S. healthcare business came in at $68.3 billion, up 11.4% from a year earlier
Reports Q2 adj.profit of $4.42 per share, beating analysts' estimates of $4.11 per share, as per data compiled by LSEG
"The fact that COR has now increased guidance 4x so far in FY25 (this is only the second fiscal quarter report) shows underlying confidence in the business as well"- brokerage Leerink Partners
Including session moves, stock up 36.6% YTD